Armstrong Shaw Associates Inc. CT decreased its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 4.7% during the third quarter, Holdings Channel reports. The fund owned 79,971 shares of the company’s stock after selling 3,956 shares during the period. Thermo Fisher Scientific accounts for 3.2% of Armstrong Shaw Associates Inc. CT’s portfolio, making the stock its 16th largest position. Armstrong Shaw Associates Inc. CT’s holdings in Thermo Fisher Scientific were worth $12,720,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in the stock. Mycio Wealth Partners LLC boosted its stake in Thermo Fisher Scientific by 1.6% in the second quarter. Mycio Wealth Partners LLC now owns 711 shares of the company’s stock worth $105,000 after buying an additional 11 shares during the period. Parsec Financial Management Inc. boosted its stake in Thermo Fisher Scientific by 0.6% in the third quarter. Parsec Financial Management Inc. now owns 1,938 shares of the company’s stock valued at $308,000 after buying an additional 12 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in Thermo Fisher Scientific by 0.6% in the third quarter. Quadrant Capital Group LLC now owns 2,844 shares of the company’s stock valued at $442,000 after buying an additional 18 shares during the last quarter. Savant Capital LLC boosted its stake in Thermo Fisher Scientific by 1.2% in the third quarter. Savant Capital LLC now owns 1,718 shares of the company’s stock valued at $273,000 after buying an additional 20 shares during the last quarter. Finally, Smithfield Trust Co. boosted its stake in Thermo Fisher Scientific by 0.5% in the second quarter. Smithfield Trust Co. now owns 5,658 shares of the company’s stock valued at $836,000 after buying an additional 29 shares during the last quarter. Institutional investors and hedge funds own 87.29% of the company’s stock.
Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at 140.98 on Wednesday. The stock has a market cap of $55.69 billion, a price-to-earnings ratio of 28.18 and a beta of 1.17. Thermo Fisher Scientific Inc has a 12 month low of $119.75 and a 12 month high of $160.68. The firm has a 50-day moving average price of $143.75 and a 200-day moving average price of $150.22.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, October 27th. The company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.97 by $0.06. The business had revenue of $4.49 billion for the quarter, compared to analyst estimates of $4.39 billion. Thermo Fisher Scientific had a net margin of 11.10% and a return on equity of 14.95%. The company’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.80 earnings per share. Equities analysts expect that Thermo Fisher Scientific Inc will post $8.24 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Monday, January 16th. Stockholders of record on Thursday, December 15th were given a $0.15 dividend. The ex-dividend date was Tuesday, December 13th. This represents a $0.60 annualized dividend and a dividend yield of 0.43%. Thermo Fisher Scientific’s dividend payout ratio is presently 12.00%.
Several equities research analysts recently issued reports on TMO shares. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $172.00 price objective on the stock in a report on Thursday, October 13th. Bank of America Corporation set a $180.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Friday, October 7th. Leerink Swann reiterated a “buy” rating and issued a $175.00 price objective on shares of Thermo Fisher Scientific in a report on Sunday, November 20th. Jefferies Group LLC lowered their price objective on Thermo Fisher Scientific from $163.00 to $160.00 and set a “hold” rating on the stock in a report on Monday. Finally, Goldman Sachs Group, Inc. (The) reiterated a “conviction-buy” rating and issued a $168.00 price objective (down from $170.00) on shares of Thermo Fisher Scientific in a report on Monday, December 12th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $165.58.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).